Latest News and Press Releases

Intern viden GenSci tildeles eksklusive rettigheder til ALK’s AIT-produkter mod husstøvmideallergi i Kina.ALK vil være berettiget til upfront- og milepælsbetalinger på op til DKK 1,3 milliarder ud...

Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to...

ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray neffy® in US patients experiencing anaphylaxis symptoms during...

ALK (ALKB:DC / OMX: ALK B) har i dag annonceret en beslutning om, at geografiske nøglemarkeder skal indgå i selskabets øverste ledelse, det såkaldte Executive Leadership Team (ELT), for at styrke...

ALK (ALKB:DC / OMX: ALK B) today announced the decision to elevate its key commercial regions into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s strategy, Allergy+. ...

Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an...

ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe...

ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for første halvår (Q2) af 2025 om morgenen torsdag den 21. august 2025. ALK afholder senere samme dag kl. 13.30 en præsentation for investorer og...

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning on Thursday, 21 August 2025. Later on the same day, the company will host a presentation for...

Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret. Omsætningen forventes nu at stige med 12-14% i lokale valutaer (mod tidligere:...